Glaukos (NYSE:GKOS – Get Free Report) and Iradimed (NASDAQ:IRMD – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.
Insider and Institutional Ownership
99.0% of Glaukos shares are held by institutional investors. Comparatively, 92.3% of Iradimed shares are held by institutional investors. 6.4% of Glaukos shares are held by insiders. Comparatively, 42.6% of Iradimed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations and price targets for Glaukos and Iradimed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Glaukos | 0 | 3 | 8 | 0 | 2.73 |
| Iradimed | 0 | 0 | 3 | 0 | 3.00 |
Earnings & Valuation
This table compares Glaukos and Iradimed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Glaukos | $341.73 million | 19.66 | -$134.66 million | ($2.88) | -46.31 |
| Iradimed | $69.48 million | 9.44 | $17.19 million | $1.41 | 36.74 |
Iradimed has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Glaukos and Iradimed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Glaukos | -47.39% | -22.51% | -12.36% |
| Iradimed | 26.83% | 24.71% | 20.86% |
Volatility & Risk
Glaukos has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Summary
Iradimed beats Glaukos on 9 of the 14 factors compared between the two stocks.
About Glaukos
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
About Iradimed
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
